Business
Contract for COVID-19 Vaccine Trial
Contract for COVID-19 Vaccine Trial.
About this update from Hvivo Plc
[{"type":"text","content":"\n \n \n RNS Number : 2256U\n Open Orphan PLC\n 28 July 2020\n \n \n \n \n 28 July 2020\n \n \n Open Orphan plc\n \n \n (\"Open Orphan\" or the \"Company\")\n \n \n Awarded Contract from Codagenix Inc. New York USA for COVID-19 Vaccine Trial\n \n \n Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce a new contract with Codagenix Inc. (\"Codagenix\") to conduct a first in human (Phase I) trial evaluating safety and immunogenicity of a single-dose, intranasal SARS-CoV-2 (COVID-19) vaccine candidate in 48 healthy young adult volunteers.\n \n \n \n \n \n Highlights:\n \n \n · \n First in human (Phase I) study of CodaVax-COVID, a codon deoptimized SARS-CoV-2 (COVID-19) single-dose, intranasal vaccine candidate \n \n \n · \n Vaccine being trialled at hVIVO's state-of-the-art Quarantine Facility in Whitechapel in London\n \n \n · \n Phase I study to start in early Autumn with initial data expected by the end of 2020\n \n \n · \n Study will include second dose as surrogate viral challenge at Day 28\n \n \n \n \n \n hVIVO, part of Open Orphan, will conduct the COVID-19 vaccine trial for Codagenix at its state-of-the-art Quarantine Facility. CodaVax-COVID is a live-attenuated vaccine that replicates very slowly, but contains all SARS-CoV-2 proteins, unlike most other vaccines that only contain the viral spike. This vaccine has the potential to induce broad antibody, cellular and mucosal immunity with a single intranasal dose. hVIVO is currently kicking off the initial steps of this exciting study and are expected to start the trial in the quarantine unit this autumn. \n \n \n \n \n \n This contract reinforces Open Orphan's position as the world leader in the testing of vaccines and antivirals.\n \n \n \n \n \n Cathal Friel, Executive Chairman, Open Orphan, said:\n \n \n \n \n \n \"We are proud to be conducting this Phase I study for Codagenix, a leader in their field, as it will help bring a promising vaccine candidate to the public to help combat the COVID-19 pandemic as quickly as possible.\n \n \n \n \n \n hVIVO, with its unique quarantine facility, is one of the few organisations in the world that has now publicly stat...